Science Journal of Medicine and Clinical Trials
November 2014,Volume 2014, ISSN: 2276-7487
© Author(s) 2014. This work is distributed under the Creative Commons Attribution 3.0 License.
Therapeutic Measures against the Current Virulent Endemicity of Ebola Virus
Emmanuel Oluwatosin Adegbite
Department of Medicine and Surgery, AfeBabalola University, Ado-Ekiti(ABUAD), Km 8.5AfeBabalola way, Ado-Ekiti, Ekiti state, Nigeria.
Accepted 20 October, 2014; Available Online 3 November,2014
Given the current situation of the third and the worst outbreak of Ebola Virus disease in Africa and of course in the world, there have been rising concerns on the evolution of different strains of Ebola virus that have been discovered and isolated during these outbreaks. This enough is a compelling warning of impending more virulent strains future outbreaks with devastating consequences. In events that culminate in the loss of vascular integrity, release of cyclooxygenase II (COX II) which results in pain, diarrhea and even shock, Ebola virus 'engineers' the host cells to synthesize the virus' proteins into the body instead of the normal host proteins. Ebola virus attaches itself to the cell membrane and the viral RNA is released into the cytoplasm where it directs the synthesis of new viral proteins and genetic material. New viral genomes are rapidly coated in protein to create cores. Ebola virus RNA polymerase binds to a single promoter located at the 3' end of the genome. Genes close to the 3' end of the genome are transcribed in greatest abundance, whereas those toward the 5' end are least likely to be transcribed. The gene order is, therefore, a simple but effective form of transcriptional regulation.
Keyword: Ebola virus; Vaccine; Antigen-antibody immune responses; Inoculation; Interferons; Gene